LOQTORZI Concentrate for solution for infusion Ref.[115078] Active ingredients: Toripalimab

Source: European Medicines Agency (EU)  Revision Year: 2025  Publisher: Topalliance Biosciences Europe Limited, Ground Floor, Two Dockland Central, Guild Street, I.f.s.c., Dublin 1, Co. Dublin, D01 K2C5, Ireland

Product name and form

LOQTORZI 240 mg concentrate for solution for infusion.

Pharmaceutical Form

Concentrate for solution for infusion.

Clear to slightly opalescent, colourless to slightly yellow solution essentially free from visible particles. The concentrate for solution has a pH of 5.5 – 6.5 and an osmolality of 260-340 mOsmol/kg.

Qualitative and quantitative composition

One vial of concentrate for solution for infusion contains 240 mg of toripalimab.

Each mL of concentrate for solution for infusion contains 40 mg of toripalimab.

Toripalimab is an immunoglobulin G4 (IgG4) humanised monoclonal antibody (mAb), produced in Chinese hamster ovary cells by recombinant DNA technology.

For the full list of excipients, see section 6.1

Active Ingredient

Toripalimab is a humanised IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumour immune response. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation, cytokine production, and cytotoxic activity.

List of Excipients

Citric acid monohydrate
Mannitol
Polysorbate 80
Sodium chloride
Sodium citrate dihydrate
Water for injections

Pack sizes and marketing

Type 1 neutral borosilicate glass vial capped sealed with a chlorobutyl rubber stopper and sealed with a 20 mm flip-off seal (aluminium), containing 6 mL of concentrate for solution for infusion.

Each carton contains one vial.

Marketing authorization holder

Topalliance Biosciences Europe Limited, Ground Floor, Two Dockland Central, Guild Street, I.f.s.c., Dublin 1, Co. Dublin, D01 K2C5, Ireland

Marketing authorization dates and numbers

EU/1/24/1853/001

Date of first authorisation: 19-09-2024

Drugs

Drug Countries
LOQTORZI Austria, Lithuania, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.